Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9040346 | 0.85 | LMNA (0.47) | LMNAKMT2APKML3MBTL1MCOLN3 | |
| SCHEMBL30156583 | 0.78 | F2 (0.43) | LMNAPKML3MBTL1TDP1GAA | |
| SCHEMBL30156675 | 0.78 | F2 (0.43) | LMNAPKML3MBTL1TDP1GAA | |
| SCHEMBL15000836 | 0.76 | LMNA (0.55) | LMNAKMT2APKML3MBTL1MCOLN3 | |
| SCHEMBL6115267 | 0.76 | LMNA (0.55) | LMNAKMT2APKML3MBTL1MCOLN3 | |
| SCHEMBL743574 | 0.76 | GAA (0.44) | KMT2AGAAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL9442565 | 0.73 | L3MBTL1 (0.56) | LMNAKMT2APKML3MBTL1MCOLN3 | |
| SCHEMBL2880572 | 0.72 | L3MBTL1 (0.55) | LMNAKMT2APKML3MBTL1MCOLN3 | |
| SCHEMBL10540594 | 0.72 | KAT6A (0.43) | LMNAKMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL25702822 | 0.71 | LMNA (0.40) | LMNAKMT2APKML3MBTL1MCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760737-B2 | Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine | ADVERIO PHARM GmbH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-20220089554-A1 | PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE | ADVERIO PHARMA GMBH (DE) | 2022-03-24 | — | — | US | disclosed |
| EP-3914588-A1 | PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE | Adverio Pharma GmbH (DE) | 2021-12-01 | — | — | EP | disclosed |
| CN-113272286-A | Process for preparing 4- (2,2,3, 3-tetrafluoropropyl) morpholine | 阿德弗里奥药品有限责任公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020152010-A1 | PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE | ADVERIO PHARMA GMBH (DE) | 2020-07-30 | — | — | WO | disclosed |
| EP-0402989-B1 | Antifungal 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]triazolones and imidazolones | JANSSEN PHARMACEUTICA NV (BE) | 1996-04-03 | — | — | EP | disclosed |
| US-5075309-A | For prevention and treatment of fungal diseases in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-12-24 | — | — | US | disclosed |
| EP-0402989-A2 | Antifungal 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]triazolones and imidazolones | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089554-A1 | PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE | CYP4F3, CYP4F2, TNNT2 | LMNA 898/4885KMT2A 2973/4885PKM 1200/4885 |
| US-11760737-B2 | Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine | CYP4F3, CYP4F2, TNNT2 | LMNA 898/4885KMT2A 2973/4885PKM 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.